News inferno.com contacted Jerrold S. Parker, a partner in New York personal injury law firm of Parker & Waichman, for his thoughts since his firm represents estate of one of patients who died from a confirmed case of PML while taking Tysabri. He stated: “This is just another example of a pharmaceutical company placing profits above public’s safety. Rather than lose money it took to bring a questionable drug to market, Biogen and Elan will do anything they can to recover their investment and more. The real question is; at what point will Tysabri become unmarketable and fall by wayside with all of other drugs that have proven to be too dangerous to continue selling to a trusting public?”

This agreement involves claimants who have allegedly developed diabetes-related side effects from their use of drug Zyprexa. Those who are not covered by final settlement are those who are represented by attorneys not participating in agreement in principle. Lilly is ready to continue their forceful defense of Zyprexa in remaining cases.

Investors have been advised that at least $700 million pretax will be taken in 2nd quarter of 2005 to cover this settlement and as well as other product liability claims. To learn more about this recent Zyprexa settlement by Eli Lilly and Company please visit http://www.resource4zyprexainfo.com